CN111110825A

CN111110825A - Composition for reducing uric acid and preparation method and application thereof

Info

Publication number: CN111110825A
Application number: CN201911402550.5A
Authority: CN
Inventors: 刘明秋; 王安; 刘德龙; 侯军红; 安心; 万举玺; 方月哏旺
Original assignee: Chengdu Yikangtang Pharmaceutical Co ltd; Yunnan Zhongke Bencao Science & Technology Co ltd
Current assignee: Chengdu Yikangtang Pharmaceutical Co ltd; Yunnan Zhongke Bencao Science & Technology Co ltd
Priority date: 2019-12-30
Filing date: 2019-12-30
Publication date: 2020-05-08

Abstract

The invention provides a composition for reducing uric acid, which is prepared from the following components in parts by weight: 50-65 parts of sunflower disc, 2-3 parts of chitin, 10-21 parts of marine fish oligopeptide powder, 35-50 parts of gynura procumbens, 15-21 parts of medlar, 12-18 parts of mulberry leaves, 26-34 parts of lindera aggregata leaves and 35-52 parts of poria cocos. The invention also provides a preparation method and application thereof. The composition prepared by the method can obviously reduce uric acid, and has obvious treatment effect; is suitable for being used as medicated food for patients with high uric acid, and has good application prospect.

Description

Composition for reducing uric acid and preparation method and application thereof

Technical Field

The invention belongs to the technical field of medicines, and particularly relates to a composition for reducing uric acid, and a preparation method and application thereof.

Background

Long-term purine metabolic disorders and/or decreased uric acid excretion can lead to elevated levels of uric acid in the blood (hyperuricemia/hyperuricemia), and about 5% to 12% of patients with hyperuricemia can eventually develop gout. In recent years, living standard is improved, dietary structure is changed, obese people are increased, incidence rates of hyperuricemia and gout are increased year by year, and it is estimated that people with high blood uric acid value in China are about 1.2 hundred million (about 9 percent of the total population) and gout patients are over 1200 ten thousand. Recent studies have shown that: hyperuricemia is not only the most important biochemical basis of gout, but also an independent risk factor causing cardiovascular death, and is closely related to metabolic disturbance syndrome and insulin resistance syndrome. Hyperuricemia has become a metabolic disease seriously threatening the health of human beings, but the drugs for treating gout and hyperuricemia are very limited, except that the gout patients are treated symptomatically by colchicine, non-steroidal anti-inflammatory drugs, glucocorticoid and the like, the drugs mainly depend on uric acid reducing drugs, such as allopurinol and benzbromarone, and the drugs have certain toxic and side effects on human bodies after being taken for a long time.

Disclosure of Invention

In order to solve the problems in the prior art, the invention provides a composition for reducing uric acid, and a preparation method and application thereof.

The technical scheme adopted by the invention for solving the technical problem is as follows:

the composition for reducing the uric acid is prepared from the following components in parts by weight: 50-65 parts of sunflower disc, 2-3 parts of chitin, 10-21 parts of marine fish oligopeptide powder, 35-50 parts of gynura procumbens, 15-21 parts of medlar, 12-18 parts of mulberry leaves, 26-34 parts of lindera aggregata leaves and 35-52 parts of poria cocos.

Preferably, the composition is prepared from the following components in parts by weight: 65 parts of sunflower disc, 3 parts of chitin, 15 parts of marine fish oligopeptide powder, 40 parts of gynura procumbens, 15 parts of medlar, 12 parts of mulberry leaves, 26 parts of combined spicebush leaves and 52 parts of poria cocos.

A preparation method of a composition for reducing urea content comprises the following steps:

(1) adding water into sunflower discs according to the formula amount, extracting and filtering to obtain an extracting solution, performing enzymolysis by using compound protease, centrifuging, filtering and concentrating to obtain an extract;

wherein the compound protease is obtained by deeply fermenting Aspergillus oryzae;

(2) adding water in an amount which is 20 times the weight of the chitin according to the formula amount, and stirring to fully absorb water;

(3) uniformly mixing the products obtained in the steps (1) and (2), adding the ocean fish oligopeptide powder according to the formula amount, and performing spray drying to obtain dry powder;

(4) mixing Gynura procumbens, medlar, mulberry leaf, lindera aggregate leaf and tuckahoe according to the formula ratio, adding water for extraction, filtering, concentrating, and spray drying to obtain dry extract powder;

(5) and (4) mixing the dry powder obtained in the step (3) and the extract dry powder obtained in the step (4) to obtain the composition.

Preferably, in the step (1),

the extraction method comprises the following steps: extracting with water for 2 times, wherein the first time is adding 18-20 times of water by weight, soaking at 65 deg.C for 30min, extracting at 95-100 deg.C for 1.5 hr, and filtering; adding 8-10 times of water for the second time, extracting under the same conditions as the first extraction method, and mixing the filtrates;

and/or

The enzymolysis method comprises the following steps: adding 5 per mill of compound protease in mass percent into the extracting solution, and stirring and carrying out enzymolysis for 2-4 hours at the temperature of 38-60 ℃;

and/or

The concentration is as follows: concentrating by two-effect concentration method until the relative density is 1.02-1.03 at 65-70 deg.C.

Preferably, in step (3), the parameters of the spray drying are as follows: the inlet air temperature is 150-165 ℃, the outlet air temperature is 85-95 ℃, the feeding speed is 3.5-4.0Hz, and the tower pressure difference is kept between-100 Pa and-200 Pa.

Preferably, in the step (4),

the extraction method comprises the following steps: mixing Gynura procumbens, fructus Lycii, folium Mori, folium Linderae and Poria, extracting with water for 2 times, wherein the water is 18-20 times the weight of the first time, extracting at 100 deg.C for 1 hr, and filtering; adding 8-10 times of water for the second time, extracting with the same method as the first extraction method, and mixing the filtrates;

and/or

The concentration method comprises the following steps: concentrating by two-effect concentration method until the relative density is 1.01-1.03 at 65-70 deg.C;

and/or

The parameters of the spray drying are as follows: the inlet air temperature is 150-160 ℃, the outlet air temperature is 80-90 ℃, the feeding speed is 3.5-4.0Hz, and the tower body pressure difference is kept between-100 Pa and-200 Pa.

The composition is applied to the preparation of medicines, health-care foods or food compositions for reducing the uric acid.

A medicine, health food or food composition comprises the above composition as effective component.

Preferably, the composition also comprises auxiliary materials or auxiliary components which are acceptable in the fields of pharmacy, health products or food.

The composition prepared by the method can obviously reduce uric acid, and has obvious treatment effect; is suitable for being used as medicated food for patients with high uric acid, and has good application prospect.

Drawings

The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention. In the drawings:

fig. 1 is a macroscopic observation of the kidney.

Fig. 2 is a kidney histopathology picture.

Detailed Description

The following examples are given to facilitate a better understanding of the invention, but do not limit the invention. The experimental procedures in the following examples are conventional unless otherwise specified. The test materials used in the following examples were purchased from conventional biochemicals, unless otherwise specified. The quantitative tests in the following examples, all set up three replicates and the results averaged.

The composition for reducing the uric acid comprises the following raw material medicines in parts by weight:

50-65 parts of sunflower disc, 2-3 parts of chitin, 10-21 parts of marine fish oligopeptide powder (Beijing Sheng Mei Nuo biotechnology Co., Ltd., molecular weight 1500-2000D), 35-50 parts of gynura procumbens, 15-21 parts of medlar, 12-18 parts of mulberry leaf, 26-34 parts of combined spicebush leaf and 35-52 parts of poria cocos.

The preparation method of the composition for reducing the uric acid comprises the following steps:

extracting sunflower disc

The preparation method of the sunflower disc comprises the following steps:

1. pretreatment: sorting the raw materials, removing impurities and worm-eaten and mildewed products, then cutting and shearing into 2-5 cm strips.

2. Extracting and filtering: putting 50-65 parts by weight of sunflower disc into a multifunctional extraction tank. Adding water with the weight 18-20 times of that of a sunflower disc for the first time, soaking for 30 minutes at 65 ℃, opening a steam valve, adjusting the pressure in an extraction tank to be not more than 0.2MPa, opening steam, heating to slightly boil, timing, keeping the temperature at 95-100 ℃ for extraction for 1.5 hours, firstly sieving with a 20-mesh sieve, then filtering with a 100-mesh filter cloth, and discharging the liquid in an enzymolysis tank; adding water with the weight 8-10 times of that of the sunflower discs for the second time, extracting again according to the first extraction method, discharging the liquid into an enzymolysis tank, merging the two filtrates into the enzymolysis tank, adding 5 per mill (w/w) of compound protease, stirring and performing enzymolysis for 2-4 hours at the temperature of 38-60 ℃, then performing high-speed centrifugation at 14000r/min, filtering the centrifugate by a ceramic membrane, and repeatedly centrifuging the unfiltered liquid and impurities until the ceramic membrane has no filter substances.

The preparation method of the compound protease comprises the following steps: aspergillus oryzae is selected as a strain, rice bran, corn flour and bean cake powder are used as culture mediums, and calcium phosphate salt is added. The inoculation amount is 5 percent of the culture medium, and the fermentation broth is obtained through deep fermentation. The fermentation liquor is filtered, ultrafiltered (100 nanometers), decompressed, concentrated and dried in vacuum to obtain the finished product of the compound protease.

In the culture medium, the weight parts of each substance are as follows: 3 parts of rice bran, 1 part of corn flour, 1 part of bean cake powder, 0.1 part of calcium phosphate and 4.9 parts of water.

The sunflower discs are firstly extracted by water and then are subjected to enzymolysis by compound protease, so that the purposes are as follows: the crude protein in the sunflower disc water extract is hydrolyzed into micromolecular polypeptide by using the compound protease, so that the subsequent processing is convenient, the absorption efficiency of the micromolecular polypeptide is high, and the effect is better than that of protein.

3. Concentration: pumping the filtrate into a two-effect concentrator to concentrate the filtrate until the relative density is 1.02-1.03 (65-70 ℃). The primary concentration temperature is 60-75 ℃, and the vacuum degree is 0.03-0.05 MPa; the temperature of the two-effect concentration is 50-55 ℃, the vacuum degree is 0.03-0.07 MPa, and the steam pressure is 0.06-0.10 MPa. The extract yield is 100-120%, and the extract is reserved.

(II) chitin treatment

Adding 2-3 parts by weight of chitin into water 20 times of the weight of the raw materials, and stirring for 1 hour to fully absorb water for later use.

(III) mixing and spray drying

And (3) mixing the products of the step (I) and the step (II) while stirring for 30 minutes, adding 10-21 parts by weight of marine fish oligopeptide powder, and performing spray drying on the obtained mixture. Controlling the steam pressure between 0.4MPa and 0.5MPa, setting the air inlet temperature of the spray dryer to be 150-165 ℃ and the air outlet temperature to be 85-95 ℃, sending the mixture into the spray dryer, setting the feeding speed to be 3.5-4.0Hz, keeping the tower body pressure difference between-100 Pa and-200 Pa, collecting the dried powder, setting the yield of the dried powder to be 10.0-12.5 percent, filling the dried powder into a packaging bag, not exceeding the bag volume of 2/3, vacuumizing and sealing the packaging bag by using a vacuum machine, weighing and labeling for later use.

The ocean fish oligopeptide powder has the following functions: the marine fish oligopeptide powder has the effects of lubricating bone joints and repairing cartilage.

(IV) extraction of the raw materials

1. Pretreatment: sorting the raw materials, removing impurities and worm-eaten and mildewed products, and removing non-edible parts.

2. Extraction: mixing 35-50 parts of gynura procumbens, 15-21 parts of medlar, 12-18 parts of mulberry leaves, 26-34 parts of lindera aggregata leaves and 35-52 parts of poria cocos, and putting into a multifunctional extraction tank. Adding 18-20 times of water, opening a steam valve, regulating the pressure in an extraction tank not to exceed 0.2MPa, opening steam, heating to slightly boil, keeping at 100 deg.C for 1 hr, sieving with a 20-mesh sieve, filtering with a 100-mesh filter cloth, and discharging the liquid in a liquid storage tank; adding water 8-10 times the weight of the raw materials for the second time, extracting again according to the first extraction method, discharging the liquid in a liquid storage tank, and combining the two filtrates in the liquid storage tank.

3. Concentration: pumping the filtrate into a two-effect concentrator to concentrate the filtrate to a relative density of 1.01-1.03 (65-70 ℃). The primary concentration temperature is 60-75 ℃, and the vacuum degree is 0.03-0.05 MPa; the temperature of the two-effect concentration is 50-55 ℃, the vacuum degree is 0.03-0.07 MPa, and the steam pressure is 0.06-0.10 MPa. The yield of the extract is 65-70%, and the extract is reserved.

And (V) feeding the extract obtained in the step (IV) into a spray dryer. Controlling the steam pressure between 0.4MPa and 0.5MPa, setting the air inlet temperature of the spray dryer to be 150-160 ℃, the air outlet temperature to be 80-90 ℃, the feeding speed to be 3.5-4.0Hz, keeping the tower body pressure difference to be-100 Pa to-200 Pa, collecting the dry extract powder, wherein the yield is 10-15%, filling the dry extract powder into a packaging bag, the volume of the packaging bag is not more than 2/3, vacuumizing and sealing by using a vacuum machine, weighing and labeling for later use.

(VI) mixing: and (4) mixing the dry powder obtained in the step (three) and the extract dry powder obtained in the step (five) to obtain the composition.

Obtaining of composition oral liquid:

(1) blending: putting the composition obtained in the step (six) into a preparation tank, adding purified water with equal weight, heating to 50 ℃ by steam, stirring to be uniform while heating, adding xylitol, slowly adding the purified water to ensure that the weight percentage content of the composition (namely solid) in the solution is between 25 and 27 percent, and adjusting the pH value to 6.5.

(2) Filling: 20m 1/bottle.

(3) And (3) sterilization: sterilizing at 108 deg.C for 30 min.

(4) And (6) packaging.

Example 1

The composition for reducing the uric acid comprises the following raw material medicines:

6.5kg of sunflower disc, 0.3kg of chitin, 1.5kg of marine fish oligopeptide powder, 4kg of gynura procumbens, 1.5kg of medlar, 1.2kg of mulberry leaf, 2.6kg of combined spicebush root leaf and 5.2kg of tuckahoe.

extracting sunflower disc

The preparation method of the sunflower disc comprises the following steps:

1. pretreatment: sorting raw materials, removing impurities and worm-eaten and mildewed products, cutting, and shearing into 2cm strips.

2. Extracting and filtering: placing 6.5kg sunflower disc in a multifunctional extraction tank. Adding water with the weight 20 times of that of the sunflower discs for the first time, soaking for 30 minutes at 65 ℃, opening a steam valve, adjusting the pressure in an extraction tank to be not more than 0.2MPa, opening steam, heating to slightly boil, timing, keeping the temperature at 98 ℃ for extraction for 1.5 hours, sieving with a 20-mesh sieve, filtering with a 100-mesh filter cloth, and discharging the liquid in an enzymolysis tank; adding water with the weight 10 times that of the sunflower discs for the second time, extracting again according to the first extraction method, discharging the liquid into an enzymolysis tank, merging the two filtrates into the enzymolysis tank, adding 5 per mill (w/w) of compound protease, stirring and performing enzymolysis for 3 hours at 50 ℃, then centrifuging at high speed at 14000r/min, filtering the centrifugate through a ceramic membrane, and repeatedly centrifuging the unfiltered liquid and impurities until the ceramic membrane has no filter substances.

3. Concentration: the filtrate was pumped into a two-way concentrator and concentrated to a relative density of 1.02(68 ℃). The primary concentration temperature is 68 ℃, and the vacuum degree is 0.04 MPa; the temperature of the two-effect concentration is 52 ℃, the vacuum degree is 0.05MPa, and the steam pressure is 0.07 MPa. The yield of the extract is 110 percent, and the extract is reserved.

(II) chitin treatment

Adding 0.3kg chitin into water 20 times of the weight of the raw materials, and stirring for 1 hour to fully absorb water for later use.

(III) mixing and spray drying

And (3) mixing the products of the step (I) and the step (II) while stirring for 30 minutes, adding 1.5kg of marine fish oligopeptide powder, and performing spray drying on the obtained mixture. Controlling the steam pressure at 0.4MPa, setting the inlet air temperature of the spray dryer to be 150 ℃ and the outlet air temperature to be 85 ℃, sending the mixture into the spray dryer, setting the feeding speed to be 3.8Hz, keeping the tower body pressure difference at-150 Pa, collecting the dry powder, putting the dry powder into a packaging bag with the yield of 12.3 percent and the volume of the packaging bag not exceeding 2/3, vacuumizing and sealing the packaging bag by using a vacuum machine, weighing and labeling for later use.

(IV) extraction of the raw materials

2. Extraction: 4kg of gynura procumbens, 1.5kg of medlar, 1.2kg of mulberry leaves, 2.6kg of combined spicebush leaves and 5.2kg of tuckahoe are mixed and put into a multifunctional extraction tank. Adding water 20 times the weight of the raw materials for the first time, opening a steam valve, adjusting the pressure in an extraction tank not to exceed 0.2MPa, opening steam, heating to slightly boil, timing, keeping at 100 ℃ for extraction for 1 hour, firstly sieving with a 20-mesh sieve, filtering with 100-mesh filter cloth, and discharging the liquid in a liquid storage tank; adding water 8 times the weight of the raw materials for the second time, extracting again according to the first extraction method, discharging the liquid in a liquid storage tank, and combining the two filtrates in the liquid storage tank.

3. Concentration: the filtrate was pumped into a two-way concentrator and concentrated to a relative density of 1.01(66 ℃). The first-effect concentration temperature is 70 ℃, and the vacuum degree is 0.03 MPa; the temperature of the two-effect concentration is 50 ℃, the vacuum degree is 0.06MPa, and the steam pressure is 0.09 MPa. The yield of the extract is 69 percent, and the extract is reserved.

And (V) feeding the extract obtained in the step (IV) into a spray dryer. Controlling the steam pressure at 0.5MPa, setting the inlet air temperature of the spray dryer at 150 ℃, the outlet air temperature at 80 ℃, the feeding speed at 3.5Hz, keeping the pressure difference of the tower body at-200 Pa, collecting dry extract powder with the yield of 15 percent, filling the dry extract powder into a packaging bag with the volume not exceeding 2/3 of the bag, vacuumizing by using a vacuum machine, sealing, weighing a label, and keeping for later use.

Obtaining of composition oral liquid:

(1) blending: putting the composition obtained in the step (six) into a preparation tank, adding purified water with equal weight, heating to 50 ℃ by steam, stirring to be uniform while heating, adding xylitol, slowly adding the purified water to ensure that the weight percentage content of the composition (namely solid) in the solution is 27%, and adjusting the pH to 6.5.

(2) Filling: 20m 1/bottle.

(3) And (3) sterilization: sterilizing at 108 deg.C for 30 min.

(4) And (6) packaging.

Example 2

5.0kg of sunflower disc, 0.2kg of chitin, 1.0kg of marine fish oligopeptide powder, 5.0kg of gynura procumbens, 2.1kg of medlar, 1.5kg of mulberry leaf, 3.4kg of lindera aggregata leaf and 4.2kg of tuckahoe.

extracting sunflower disc

The preparation method of the sunflower disc comprises the following steps:

2. Extracting and filtering: placing 5kg sunflower disc in a multifunctional extraction tank. Adding water 19 times the weight of the sunflower disc for the first time, soaking for 30 minutes at 65 ℃, opening a steam valve, adjusting the pressure in an extraction tank to be not more than 0.2MPa, opening steam, heating to slightly boil, timing, keeping the temperature at 100 ℃ for extraction for 1.5 hours, sieving with a 20-mesh sieve, filtering with a 100-mesh filter cloth, and discharging the liquid in an enzymolysis tank; adding water 9 times the weight of the sunflower discs for the second time, extracting again according to the first extraction method, discharging the liquid into an enzymolysis tank until the two filtrates are combined in the enzymolysis tank, adding 5 per mill (w/w) of compound protease, stirring and performing enzymolysis for 2 hours at 60 ℃, then centrifuging at high speed at 14000r/min, filtering the centrifugate by a ceramic membrane, and repeatedly centrifuging the unfiltered liquid and impurities until the ceramic membrane has no filter substances.

3. Concentration: the filtrate was pumped into a two-way concentrator and concentrated to a relative density of 1.03(65 ℃). The first-effect concentration temperature is 60 ℃, and the vacuum degree is 0.03 MPa; the temperature of the two-effect concentration is 50 ℃, the vacuum degree is 0.07MPa, and the steam pressure is 0.06 MPa. The yield of the extract is 120 percent, and the extract is reserved.

(II) chitin treatment

Adding 0.2kg chitin into water 20 times of the weight of the raw materials, and stirring for 1 hour to fully absorb water for later use.

(III) mixing and spray drying

And (3) mixing the products of the step (I) and the step (II) while stirring for 30 minutes, adding 1.0kg of marine fish oligopeptide powder, and performing spray drying on the obtained mixture. Controlling the steam pressure at 0.4MPa, setting the inlet air temperature of the spray dryer at 160 ℃ and the outlet air temperature at 95 ℃, feeding the mixture into the spray dryer at a feeding speed of 4.0Hz, keeping the tower body pressure difference at-100 Pa, collecting the dried powder, putting the dried powder into a packaging bag with the yield of 11.1 percent and the volume of the packaging bag not exceeding 2/3, vacuumizing and sealing the packaging bag by using a vacuum machine, and weighing and labeling for later use.

(IV) extraction of the raw materials

2. Extraction: mixing Gynura procumbens (lour.) Merr 5.0kg, fructus Lycii 2.1kg, folium Mori 1.5kg, folium Linderae Strychnifoliae 3.4kg, and Poria 4.2kg, and placing into a multifunctional extraction tank. Adding 18 times of water by weight of the raw materials for the first time, opening a steam valve, adjusting the pressure in an extraction tank not to exceed 0.2MPa, opening steam, heating to slightly boil, timing, keeping at 100 ℃ for extraction for 1 hour, firstly sieving with a 20-mesh sieve, filtering with 100-mesh filter cloth, and discharging the liquid in a liquid storage tank; adding water 10 times the weight of the raw materials for the second time, extracting again according to the first extraction method, discharging the liquid in a liquid storage tank, and combining the two filtrates in the liquid storage tank.

3. Concentration: the filtrate was pumped into a two-way concentrator and concentrated to a relative density of 1.02(65 ℃). The first-effect concentration temperature is 60 ℃, and the vacuum degree is 0.04 MPa; the temperature of the two-effect concentration is 52 ℃, the vacuum degree is 0.03MPa, and the steam pressure is 0.06 MPa. The yield of the extract is 65 percent, and the extract is reserved.

And (V) feeding the extract obtained in the step (IV) into a spray dryer. Controlling the steam pressure at 0.4MPa, setting the inlet air temperature of the spray dryer at 160 ℃, the outlet air temperature at 82 ℃, the feeding speed at 4.0Hz, keeping the pressure difference of the tower body at-100 Pa, collecting dry extract powder with the yield of 13%, filling the dry extract powder into a packaging bag, keeping the volume of the packaging bag to be not more than 2/3, vacuumizing by using a vacuum machine, sealing, weighing a label, and keeping for later use.

Obtaining of composition oral liquid:

(1) blending: putting the composition obtained in the step (six) into a preparation tank, adding purified water with equal weight, heating to 50 ℃ by steam, stirring to be uniform while heating, adding xylitol, slowly adding the purified water to ensure that the weight percentage content of the composition (namely solid) in the solution is 26%, and adjusting the pH to 6.5.

(2) Filling: 20m 1/bottle.

(3) And (3) sterilization: sterilizing at 108 deg.C for 30 min.

(4) And (6) packaging.

Example 3

5.8kg of sunflower disc, 0.25kg of chitin, 2.1kg of marine fish oligopeptide powder, 3.5kg of gynura procumbens, 1.8kg of medlar, 1.8kg of mulberry leaf, 2.9kg of lindera aggregate leaf and 3.5kg of tuckahoe.

extracting sunflower disc

The preparation method of the sunflower disc comprises the following steps:

2. Extracting and filtering: placing 5.8kg sunflower disc in a multifunctional extraction tank. Adding water 18 times the weight of the sunflower disc for the first time, soaking for 30 minutes at 65 ℃, opening a steam valve, adjusting the pressure in an extraction tank to be not more than 0.2MPa, opening steam, heating to slightly boil, timing, keeping the temperature at 95 ℃ for extraction for 1.5 hours, sieving with a 20-mesh sieve, filtering with 100-mesh filter cloth, and discharging the liquid in an enzymolysis tank; adding water 8 times the weight of the sunflower discs for the second time, extracting again according to the first extraction method, discharging the liquid into an enzymolysis tank until the two filtrates are combined in the enzymolysis tank, adding 5 per mill (w/w) of compound protease, stirring and performing enzymolysis for 4 hours at 38 ℃, then centrifuging at high speed at 14000r/min, filtering the centrifugate by a ceramic membrane, and repeatedly centrifuging the unfiltered liquid and impurities until the ceramic membrane has no filter substances.

3. Concentration: the filtrate was pumped into a two-way concentrator and concentrated to a relative density of 1.02(70 ℃). The first-effect concentration temperature is 75 ℃, and the vacuum degree is 0.05 MPa; the temperature of the two-effect concentration is 55 ℃, the vacuum degree is 0.03MPa, and the steam pressure is 0.10 MPa. The yield of the extract is 100 percent, and the extract is reserved.

(II) chitin treatment

Adding 0.25kg chitin into water 20 times of the weight of the raw materials, and stirring for 1 hour to fully absorb water for later use.

(III) mixing and spray drying

And (3) mixing the products of the step (I) and the step (II) while stirring for 30 minutes, adding 2.1kg of marine fish oligopeptide powder, and performing spray drying on the obtained mixture. Controlling the steam pressure at 0.5MPa, setting the inlet air temperature of the spray dryer at 165 ℃ and the outlet air temperature at 90 ℃, feeding the mixture into the spray dryer at a feeding speed of 3.5Hz, keeping the tower body pressure difference at-200 Pa, collecting the dried powder, putting the dried powder into a packaging bag with the yield of 10.0 percent and the volume of the packaging bag not exceeding 2/3, vacuumizing and sealing the packaging bag by using a vacuum machine, and weighing and labeling for later use.

(IV) extraction of the raw materials

2. Extraction: mixing Gynura procumbens 3.5kg, fructus Lycii 1.8kg, folium Mori 1.8kg, folium Linderae Strychnifoliae 2.9kg, and Poria 3.5kg, and placing into a multifunctional extraction tank. Adding water 19 times the weight of the raw materials for the first time, opening a steam valve, adjusting the pressure in an extraction tank not to exceed 0.2MPa, opening steam, heating to slightly boil, timing, keeping at 100 ℃ for extraction for 1 hour, firstly sieving with a 20-mesh sieve, filtering with 100-mesh filter cloth, and discharging the liquid in a liquid storage tank; adding water 9 times the weight of the raw materials for the second time, extracting again according to the first extraction method, discharging the liquid in a liquid storage tank, and combining the two filtrates in the liquid storage tank.

3. Concentration: the filtrate was pumped into a two-way concentrator and concentrated to a relative density of 1.03(70 ℃). The first-effect concentration temperature is 75 ℃, and the vacuum degree is 0.05 MPa; the temperature of the two-effect concentration is 55 ℃, the vacuum degree is 0.07MPa, and the steam pressure is 0.10 MPa. The yield of the extract is 70 percent, and the extract is reserved.

And (V) feeding the extract obtained in the step (IV) into a spray dryer. Controlling the steam pressure at 0.5MPa, setting the inlet air temperature of the spray dryer at 155 ℃, the outlet air temperature at 90 ℃, the feeding speed at 3.9Hz, keeping the pressure difference of the tower body at-150 Pa, collecting the dry extract powder with the yield of 10 percent, filling the dry extract powder into a packaging bag, keeping the volume of the packaging bag to be not more than 2/3, vacuumizing by using a vacuum machine, sealing, weighing a label, and keeping for later use.

Obtaining of composition oral liquid:

(1) blending: putting the composition obtained in the step (six) into a preparation tank, adding purified water with equal weight, heating to 50 ℃ by steam, stirring to be uniform while heating, adding xylitol, slowly adding the purified water to ensure that the weight percentage content of the composition (namely solid) in the solution is 25%, and adjusting the pH to 6.5.

(2) Filling: 20m 1/bottle.

(3) And (3) sterilization: sterilizing at 108 deg.C for 30 min.

(4) And (6) packaging.

EXAMPLE 4 examination of the therapeutic Effect of the drugs or health foods prepared by the method of the present invention

Firstly, the effect of the composition of the invention on the acute gouty arthritis caused by sodium urate

Acute gouty arthritis is caused by that when the crystal of the sodium urate which is an inflammation-causing factor is deposited around the joint cavity, inflammatory cells can be induced to gather around the crystal to generate phagocytosis reaction, and a plurality of inflammation-causing pain factors are released, so that a wide inflammatory reaction around the joint is caused. We observed the effect of the oral liquid composition on gouty arthritis by using a model of local gouty joint symptoms caused by injecting sodium urate into the ankle joint cavity of rats.

1 materials of the experiment

1.1 drugs and reagents

The composition oral liquid prepared according to the method of example 1, the stock solution is used in the high dose group, the medium dose group is diluted 1 time for standby, and the low dose group is diluted 3 times for standby;

tragacanth gum, Shanghai Aipi Chemicals, Inc., Lot 2007-02-04;

sodium urate (uric acid sodium salt), Sigma, lot No. BCB 57438;

colchicine tablets, Xishuangbanna pharmaceutical industry Limited liability company, lot number 171116;

pentobarbital sodium, imported for split charging, lot number 890323;

tween80, Sigma aliquoted, C283;

benzbromarone tablets, hemman pharmaceutical factory, germany, lot No. 1608096.

1.2 test animals

56 healthy male SD rats with body weight (200 + -20) g, provided by Beijing Huafukang Biotech, Inc., quality certification number: SCXK (Jing) 2014-. The product is adapted to the environment for one week before use, and is fed by common feed, freely ingested and drunk in the whole experiment process.

2 method of experiment

2.1 pharmaceutical treatment

(1) Colchicine emulsion suspension: weighing colchicine tablet, grinding with mortar, accurately weighing certain weight of powder with electronic balance, calculating colchicine content, and preparing emulsion suspension with colchicine final concentration of 8mg/100mL with 1.25% tragacanth. The medicine is administrated twice a day by intragastric administration of 0.45 mg/kg.

(2) Preparation of sodium urate solution: weighing 250mg of sodium urate, adding 9mL of physiological saline and Tween-80 lmL, emulsifying by an emulsifying machine to prepare 10mL of 2.5% sodium urate solution, and sterilizing at high temperature for later use. Control solution: and adding 1mL of Tween80 into 9mL of normal saline, and uniformly mixing.

2.2 preparation of the model

A slight improvement was made using the classical modeling method of Coderre et al. Iodine tincture disinfects the right ankle joint, a No. 6 injection needle is inserted into the inner side of a tibialis muscle cavity from the 45-degree direction at the back side of the right ankle joint of a tested rat, 0.2mL of 2.5% sodium urate solution is injected into the ankle joint cavity, stretching and rotating movement are carried out for a moment, and the circumference of the ankle joint is measured by using an oily stroke position as a mark at the same fixed position of the ankle joint.

2.3 Experimental procedure

Selecting healthy male SD rats with weight (200 +/-20) g, wherein the weight is 56, the SD rats are provided by Beijing Huafukang scientific and technology GmbH, and the rats are evenly divided into 7 groups according to a random block method: a control group (A group), a model group (B group), a positive medicine group colchicine (C group), a positive medicine group benzbromarone (D group), and a composition oral liquid group (high, medium and low dose) group (E, F, G group).

The ordinary feed is fed and adapted to the environment for 1 week, the weight is weighed, and the administration dosage is determined: group A and group B were given 1.25% tragacanth 10 mL/kg; group C administered positive drug colchicine 0.45 mg/kg; d, 10mg/kg of benzbromarone as a positive medicament is administered, and E, F, G groups of the benzbromarone are respectively administered with 2.5g/kg of the composition oral liquid of the embodiment 1 of the invention; gavage was performed daily for 7 days.

On the 4 th day of gavage (72 h), the weight was weighed again. Measuring the circumference of the right ankle joint by a line-tying method 1h after the first administration, injecting 0.2mL of control solution into the joint cavity of the control group, and injecting 0.2mL of sodium urate solution into the joint cavity of the model group to prepare the model. The same site was measured again after 0, lh,2h,4h,6h,12h,24h,48h, and 72h, respectively, so that the change in the circumference of the ankle joint before and after inflammation indicates the degree of swelling of the gouty arthritis joint.

And after 72h, measuring the circumference of the right ankle joint again and weighing the weight. After anesthesia with 0.3mL of 3% sodium pentobarbital, blood is taken from the heart, 1mL is rapidly injected into an EDTA anticoagulation tube, and the rest is injected into a common tube.

2.4 sample processing and detection

Anticoagulation: counting the white blood CELLs in a CELL-DYN-1700 CELL counter within 6 hours, and mixing the white blood CELLs before detection.

Non-anticoagulation: incubating at 37 ℃ for 30min, centrifuging at 2500r/min for 15min, and placing the supernatant in a refrigerator at-70 ℃ for freezing and storing for detection.

2.5 statistical treatment

As a result, to

Representing that analysis processing is carried out by applying sps 19.0 statistical software, the total difference between groups is tested by adopting F, the average comparison between each group is analyzed by adopting variance, the pairwise comparison between groups is tested by adopting Q, and P is carried out<0.05 the difference was considered statistically significant, P<0.01 the difference is considered to have significant statisticsThe meaning of the study.

3 results of the experiment

3.1 Effect of composition oral liquid on blood leucocyte of experimental rat

The model group has a reduction of blood leukocytes (P <0.01) compared with the control group, has a significant difference (P <0.01) compared with the colchicine group, has no significant difference (P >0.05) compared with the benzbromarone group, and has statistical significance (P <0.05 and P <0.01) compared with the model group in the high and medium dosage groups of the oral liquid composition, and is shown in table 1.

TABLE 1 oral liquid composition for treating gouty arthritis caused by sodium urate and white blood cell change in rat blood

Comparing with control group^##P is less than 0.01; comparison with model group^*P＜0.05，^**P＜0.01。

3.2 Effect of composition oral liquid on IL-1 β in serum of experimental rat

Compared with a control group, the model group has higher serum IL-1 β (P is less than 0.01), has significant difference (P is less than 0.05) compared with a colchicine group, and has no significant difference (P is more than 0.05) compared with the high, medium and low dose groups of the oral liquid composition and the model group, which is shown in a table 2.

TABLE 2 oral liquid of composition for treating gouty arthritis caused by sodium urate in rat blood IL-1 β

Comparing with control group^##P is less than 0.01; comparison with model group^*P＜0.05。

3.3 Effect of composition oral liquid on IL-6 in serum of experimental rat

Compared with the control group, the model group has higher serum IL-6 (P is less than 0.01), has significant difference (P is less than 0.05) compared with the colchicine group, and has no significant difference (P is more than 0.05) compared with the high, medium and low dose groups of the oral liquid composition and the model group, which is shown in a table 3.

TABLE 3 oral liquid of composition for treating gouty arthritis caused by sodium urate in rat blood IL-6

3.4 Effect of composition oral liquid on TNF- α in serum of experimental rat

Compared with a control group, the model group has higher serum TNF- α (P <0.01), has significant difference compared with a colchicine group (P <0.01), and has significant difference compared with the model group (P <0.05) in a composition oral liquid low-dose group, and the table 4 shows that the serum TNF- α is higher than the control group.

TABLE 4 oral liquid of composition for treating gouty arthritis caused by sodium urate in rat blood TNF- α

Comparing with control group^##P is less than 0.01; comparison with model group^**P＜0.01。

3.5 Effect of composition oral liquid on serum uric acid of experimental rat

Compared with a control group, the serum uric acid of the model group is increased (P <0.01), the serum uric acid of the model group is significantly different (P <0.01) compared with that of a colchicine group, the descending trend of the oral liquid composition in the high, medium and low dose groups is significant compared with that of the model group, and the high, medium and low dose groups have statistical significance (P <0.01) compared with that of the model group, as shown in a table 5.

TABLE 5 oral liquid composition for treating gouty arthritis caused by sodium urate experiment rat blood uric acid change

3.6 change of swelling degree of the joint circumference

The swelling degree of the joint circumference of rats in each experimental group is not obviously different after model building for 1h (P is more than 0.05), the swelling degree of the joint of rats in each group is increased after model building for 2h, and the peak is reached after 12h, wherein the most obvious model group (P is less than 0.01) is adopted, and the colchicine and benzbromarone groups have statistical significance (P is less than 0.05, P is less than 0.01) compared with the model groups for 4h,6h,12h and 24 h; the swelling degrees of the joints of the composition oral liquid in the low dose groups of 4h,6h and 12h have statistical significance (P is less than 0.05, and P is less than 0.01) compared with the model group, the swelling degrees of the joints of the composition oral liquid in the high dose group of 4h have statistical significance (P is less than 0.01) compared with the model group, and the swelling degrees of the joints of the composition oral liquid in the high dose group of 4h,6h and 12h have statistical significance (P is less than 0.01) compared with the model group, which is shown in Table 6.

Table 6 effect of oral liquid composition on gouty arthritis induced by sodium urate peripheral diameter of ankle joint of experimental rat (n-8,

)

Secondly, the effect of the composition oral liquid on the gout of experimental rats

Uric acid is the end product of purine metabolism in the body, and purine is mainly from nucleic acids and other purine compounds metabolized by cells and food. Hyperuricemia (hyperuricemia) occurs when serum uric acid is greater than or equal to 416. mu. mol/L (7.0mg/dL) regardless of men and women. When the uric acid in the body fluid exceeds the saturated concentration, the uric acid is separated out and crystallized and is deposited in soft tissues to form gout. Hyperuricemia is a prerequisite and biochemical basis for gout, which is often accompanied by hyperuricemia. Therefore, hyperuricemia and gout are often discussed together in the prevention and treatment of gout. According to the characteristics and the development period of gout, a rat hyperuricemia gout model is established, and the prevention effect and the treatment effect of the composition oral liquid on gout are researched.

1 materials of the experiment

1.1 drugs and reagents

Adenine, Beijing Solarbic Science & technology 73245;

ethambutol, available from shenyang red flag pharmaceuticals, inc, under batch number 1710021;

allopurinol, shanghai xin iewan, inc, lot number 05180303;

the traditional Chinese medicine composition oral liquid prepared in the embodiment 1 of the invention;

tragacanth gum, Shanghai Aipi Chemicals, Inc., Lot 2007-02-04;

pentobarbital sodium, imported for split charging, lot number 890323.

1.2 Experimental animals

The experimental animals are 56 healthy SD rats which are male and have the weight of 180-; the Beijing Huafukang Biotechnology Limited company provides, quality certification number: SCXK (Jing) 2014-. The product is adapted to the environment for one week before use, and is fed by common feed, freely ingested and drunk in the whole experiment process.

2 method of experiment

2.1 pharmaceutical treatment

(1) Preparation of allopurinol and adenine solutions

Firstly, preparing the tragacanth gum into a concentration of 1.25%, accurately weighing 0.9g of allopurinol powder and 4g of adenine by using an electronic balance, and then dissolving the allopurinol powder and the adenine powder into 100mL by using 1.25% of the tragacanth gum respectively to prepare an allopurinol solution with a concentration of 0.9% and an adenine solution with a concentration of 5%.

(2) Preparation of concentration of oral liquid of traditional Chinese medicine composition

The traditional Chinese medicine composition oral liquid prepared in the embodiment 1 of the invention is a stock solution for a high-dose group, a medium-dose group is diluted by 1 time for later use, and a low-dose group is diluted by 3 times for later use.

(3) Preparation of ethambutol solution

Accurately weighing 5g of ethambutol by an electronic balance, dissolving with high-pressure distilled water to 100mL, and preparing into 5% ethambutol solution.

2.2 preparation of the model

The control group was gavaged with equal volume of 1.25% tragacanth, and the remaining animals were gavaged with adenine (100mg/kg/d) and ethambutol (250mg/kg/d) daily for 21 days to cause hyperuricemia in rats.

2.3 Experimental procedure

56 healthy male SD rats weighing 200 + -20 g were randomly divided into 7 groups of 8 rats each: control group, model group, allopurinol group (45mg/kg/d), benzbromarone group 10 mg.kg^-1E, F, G group administration of composition oral liquid 2.5 g/kg; after 3 days of normal feeding, 5 days before molding, except for the control group and the model group, the same volume of 1.25% of tragacanth gum was given, and the other groups were started to administer the corresponding dose by gavage according to body weight. It is administered 1 time daily. Gavage administration was started in the morning and molding was performed in the afternoon on the sixth day for 21 consecutive days.

2.4 sample processing and detection

After the last administration for 0.5h according to the molding method, injecting 5% sodium pentobarbital solution into rats for anesthesia, taking blood from abdominal aorta of each group of rats, standing in water bath (37 ℃) until layering, centrifuging at 3000r/min for 10min, taking serum to measure each observation index, and performing interclass difference comparison. And taking 4 of the kidney in each group, picking the kidney, fixing the kidney in 10% formaldehyde solution for more than 24h, dehydrating with alcohol, and transparently soaking wax in xylene. After paraffin embedding, the slices are cut into slices with the thickness of 5 mu m, the slices are mounted on a clean glass slide and placed in a 60 ℃ thermostat for baking for 6 hours, hematoxylin 2 eosin (HE) is used for staining, and the pathological change of the kidney tissues is observed under an optical microscope.

The observed indicators were rat xanthine oxidase activity, serum levels of uric acid, creatinine, urea nitrogen concentration, and pathological changes of renal tissue, and differences between groups were compared.

2.5 statistical treatment

As a result, to

Showing that SPSS13.1 statistical software is used for analysis, the total difference among groups is tested by F, the mean of each group is compared by variance analysis, the pairwise comparison among groups is tested by Q, and P is tested<0.05 the difference was considered statistically significant, P<0.01 the difference was considered to have significant statistical significance.

3 results of the experiment

3.1 Effect of the composition oral liquid on the concentration of xanthine oxidase in rat hyperuricemia

Compared with the control group, the xanthine oxidase activity of the model group is obviously improved (P <0.01), compared with the model group, the high, medium and low dosage groups of the oral liquid composition have no obvious influence on the xanthine oxidase activity (P >0.05), compared with the model group, the allopurinol group has obviously reduced xanthine oxidase activity (P <0.01), and the benzbromarone group and the xanthine oxidase activity have no obvious influence (P >0.05), which is shown in the table 7.

TABLE 7 Effect of oral compositions on rat hyperuricemia xanthine oxidase concentration: (

n＝8)

Compared with the control group, the compound of the formula,^##P<0.01; in comparison with the set of models,^*P<0.01。

3.2 Effect of the composition oral liquid on rat hyperuricemia uric acid, urea nitrogen and creatinine values

Compared with the control group, the model group has obviously increased uric acid, blood uric acid and urea nitrogen levels (P <0.01, P < 0.05); compared with the model group, the high, medium and low dosage groups of the oral liquid of the composition have obviously reduced blood uric acid and creatinine levels (P is less than 0.01 and P is less than 0.05); the high, medium and low dose groups of the oral liquid composition have no obvious effect of reducing blood urea nitrogen (P is more than 0.05) compared with the model group, and the effect is shown in a table 8.

TABLE 8 Effect of oral composition on uric acid, urea nitrogen and creatinine values in hyperuricemia in rats: (

n＝8)

Compared with the control group, the compound of the formula,^##P<0.01; comparison with model group<0.05，**P<0.01。

3.3 Effect of the composition oral liquid on rat peripheral blood cholesterol and triglyceride

Compared with the control group, the total cholesterol level is obviously increased (P is less than 0.01), and compared with the control group, the total cholesterol level is obviously reduced (P is less than 0.05) in the middle and low dosage groups of the oral liquid composition; compared with the model group, the triglyceride level of the middle and low dosage groups of the composition oral liquid is reduced (P is less than 0.05), and the reduction effect of the high dosage group of the composition oral liquid, allopurinol and benzbromarone is not obvious (P is more than 0.05), which is shown in table 9.

TABLE 9 Effect of oral compositions on Total Cholesterol and triglyceride values in rats: (

n＝8)

Compared with the control group, the compound of the formula,^##P<0.01; comparison with model group<0.05，**P<0.01

3.4 Effect of composition oral liquid on rat Kidney weight and index

Compared with a control group, the model group has statistical significance on the influence of the kidney index of rats (P <0.01), compared with the model group, the high, medium and low dosage groups of the oral liquid composition have statistical significance on the influence of the kidney index of rats (P <0.05 and P <0.01), compared with the model group, the allopurinol group has statistical significance on the influence of the kidney index of rats (P <0.01) and the reduction effect of the benzbromarone group is not obvious (P >0.05), and the table 10 shows.

TABLE 10 Effect of oral composition on rat Kidney index: (

n＝8)

Compared with the control group, the compound of the formula,^##P<0.05; in comparison with the set of models,^*P<0.05，^**P<0.01。

3.5 Effect of the composition oral liquid on rat hyperuricemia kidney pathology

Macroscopic observation of kidney: the kidney of the model group rat is obviously enlarged and pale, and a large amount of white crystals can be seen by naked eyes; the kidneys of rats in the allopurinol group are slightly enlarged and pale; when the composition oral liquid is in a high dose group, a medium dose group, a low dose group and a benzbromarone group, the composition oral liquid is enlarged in different degrees and is reduced in different degrees compared with a model group, but a small amount of white crystals can be seen by naked eyes. The control rat kidney was red and as large as soybean. See fig. 1.

Macroscopic observation of kidney: the kidney of the rat in the model group is obviously enlarged and pale, and the large and pale white nodules of rice grains which are diffused can be seen by naked eyes; the kidneys of rats in the allopurinol group are slightly enlarged and dark red; when the high dose group, the medium dose group, the low dose group and the benzbromarone group of the composition oral liquid are enlarged in different degrees, the enlargement is reduced in different degrees compared with the model group, but large and grey white nodules scattered in the rice grains can still be seen by naked eyes, and the enlargement is reduced in comparison with the model group and the benzbromarone group. The control rat kidney was ruddy in color, like broad bean. See fig. 1.

The pathological section of kidney tissue is observed by a light microscope, wherein in a ① model group, the degeneration and necrosis of renal tubular epithelial cells in renal cortex are obvious, the expansion of a lumen is obvious, granular cast and sepia crystals formed by multifocal inflammatory necrotic tissue are seen in the lumen, partial renal tubular necrosis disappears and is replaced by hyperplastic fibrous tissues and inflammatory cells, a focal forms a small abscess, peripheral interstitial hyperemia and edema, glomerular plexus congestion and no obvious injury are seen, the renal interstitial hyperemia and edema is accompanied by infiltration of multiple lymph, mononuclear and neutral granular cells, partial lumen has protein cast and granular cast, renal pelvis mucosal focal metastatic epithelial superficial erosion is seen, the surface has multiple sepia crystals and inflammatory necrotic tissue, ureteral transitional epithelium is hyperplastic, the protein component in the lumen is seen, ② allopurinol group, the crystallization in the renal tubular epithelium is obviously reduced, the mild degeneration and necrosis of the renal tubular epithelium is seen, a small amount of protein and granular cast in the lumen is seen, the mild chronic inflammatory cell infiltration is seen, ③ composition oral liquid has dosage groups, the degeneration and necrosis of renal tubular epithelial cells in the renal cortex is obviously reduced compared with the interstitial cast in the renal cortical tissue group, the renal interstitial tissue has a high degree, the normal fibroblastic necrosis, the normal fibroblastic hyperplasia is seen, the renal interstitial tissue is also compared with the renal interstitial non-contrast sacculus in the renal interstitial tissue group, the renal interstitial tissue has a normal contrast tendency of the renal interstitial structure is also seen, the.

Fig. 1 is a macroscopic observation of the kidney.

Fig. 2 is a kidney histopathology picture; HE × 400.

Third, the safety evaluation of the composition oral liquid

Acute toxicity test is to observe acute toxicity reaction and death of the tested animals caused by large dose or excessive dose of the tested drugs in a short period (24 h). If LD cannot be detected when the toxicity of the drug is low₅₀The maximum dose can be used to evaluate the safetyAnd the method provides a reference basis for designing the dose of the vitex for clinical safe medication and long-term toxicity test. According to the technical requirement of the research on the pharmacology and toxicology of new traditional Chinese medicines issued by the State drug administration in 1999, the experiment researches the maximum dosage, LD, of the oral liquid composition₅₀>32g/kg, which shows that the safety range is large and the toxic and side effects are small.

1. Acute toxicity test of composition oral liquid mice

1.1 test drugs: the composition prepared in example 1 of the present invention. Distilled water is used for preparing composition oral liquid with the weight percentage of 80% for standby application, and the administration route is as follows: is administered orally.

1.2 test animals: adult healthy Kunming breed white mice, 40 mice, with a weight of 20 rats 1g and half female and half male, provided by Beijing Huafukang Biotechnology Limited, quality certification number: SCXK (Jing) 2014-. The animals were acclimatized for 5 days and the animal room temperature was controlled at room temperature.

1.3 test methods

1.3.1 animal groups

Before the test, 40 healthy Kunming mice are taken, half of the mice are male and female, and the weight of the mice is 20 days and 1 g. All animals were randomized in homo-sex cages into experimental and control groups: of these groups, 20 had 10 males and 10 females; the control group had 20, 10 males and 10 females, and was fasted for 12 hours after completion of the grouping without water deprivation.

1.3.2 Experimental methods

(1) Basis of dosage design

According to the results of the preliminary test, the composition oral liquid with the weight percentage of 80% is used, the volume of the oral liquid is 0.8mL/20g of mice, the oral liquid is administrated by intragastric administration once in the morning, and the mice are not dead after continuous observation for 14 days, so the maximum administration amount test is carried out.

(2) Dosage and administration method of test article

The mice were gavaged once a day in the morning with a dose of 80% of the oral liquid of the Chinese medicinal composition of 0.8mL at the maximum gavage volume, and the toxic reaction of the mice was observed. Fasting was terminated 2 hours after dosing. The control group was given 0.8mL of tap water of equal volume.

(3) Observation items and indicators

(a) Observation time: the observation was continued for 14 days.

(b) Weighing: the weight of the stored animals was weighed on the day of administration, 7 days after observation and 14 days after observation, respectively.

(c) Animal toxicity was observed: after administration, mice were observed for activity, diet, feces, respiration, body weight and death for 14 days. On day 14, 3% sodium pentobarbital was used for intraperitoneal injection for anesthesia, the dose was 40mg/kg, and the surviving animals were sacrificed, dissected, and the condition of the organs was visually observed.

1.4 test results

1.4.1 clinical characterization of mice after drenching: after the oral liquid composition is orally administered to the observed mice by gavage on the next day, the activity state, diet, feces and breath of the mice are not abnormal until the observation period is finished, and other toxic reactions are not seen.

1.4.2 acute toxicity test mice drench animal death: mice in the administration group and the control group did not die.

1.4.3 mouse body weight observations:

TABLE 11 toxicity test body weight of oral composition

The weight average of the mice is increased, and compared with the weight of a blank control group, the weight of the administration group is greater than 0.05, and the weight of the mice in two groups has no significant difference. The results show that the oral liquid of the composition has no obvious influence on the weight gain of mice after two times of large-dose oral administration.

1.4.4 after 14 days of the experiment, the experimental mice were dissected, and no obvious abnormality was observed in the visceral organ condition by naked eye observation.

1.5 conclusion

Through acute toxicity test of mice, the concentration (0.8g/mL) and the maximum volume (0.8 mL/mouse) of the oral liquid of the composition are administrated by intragastric administration once, and the maximum administration amount of the composition is determined to be 32 g/kg. Shows that the oral composition oral liquid is orally taken by mice LD₅₀>32g/kg。

Four, small knot

The invention adopts the animal models of acute gout disease and hyperuricemia which are commonly used at home and abroad, and researches the pharmacodynamics research of the composition oral liquid on the acute gout disease model and the hyperuricemia gout disease model. The results are as follows:

(1) the joint circumference of each group of rats is increased after molding and reaches a peak after 12h, wherein the most obvious effect is achieved by using a model group, and the swelling degrees of joints of colchicine groups and benzbromarone groups in 4,6,12 and 24h are reduced to different degrees with the model group (P is less than 0.05, and P is less than 0.01); the composition oral liquid has different degree of reduction in low dose groups of 4,6 and 12h and model groups (P is less than 0.05 and P is less than 0.01); the dosage groups 4 and 6 hours in the composition oral liquid and the model group are reduced to different degrees (P is less than 0.05, and P is less than 0.01), and experiments show that the composition oral liquid has certain influence on ankle swelling caused by sodium urate.

(2) The composition oral liquid has high and medium dosage, and can reduce peripheral blood leukocyte number (P <0.05, P <0.01) of rat in acute gout model.

(3) The composition oral liquid can reduce the blood uric acid content (P <0.01) of rats with acute gout model in high, medium and low dose groups.

(4) The composition can reduce the content of uric acid and creatinine in the high, medium and low dosage groups (P <0.05, P < 0.01).

(5) The composition can be used in middle and low dosage groups for reducing blood total cholesterol and triglyceride levels (P <0.05, P < 0.01).

(6) The composition oral liquid can obviously reduce the swelling degree of the kidney in high, medium and low dose groups (P is less than 0.05, and P is less than 0.01).

(7) The kidney pathological section of the model group shows that the preparation of the rat hyperuricemia model is successful; compared with the model group, the composition oral liquid has the advantages that the pathological changes of the high, medium and low dose groups are reduced to a certain extent.

(8) Acute toxicity test of mice shows that the composition oral liquid orally takes LD for the mice₅₀>32g/kg, indicating low toxicity.

Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A composition for reducing uric acid, which is characterized in that: the composition is prepared from the following components in parts by weight: 50-65 parts of sunflower disc, 2-3 parts of chitin, 10-21 parts of marine fish oligopeptide powder, 35-50 parts of gynura procumbens, 15-21 parts of medlar, 12-18 parts of mulberry leaves, 26-34 parts of lindera aggregata leaves and 35-52 parts of poria cocos.

2. The urea-lowering composition according to claim 1, wherein: the composition is prepared from the following components in parts by weight: 65 parts of sunflower disc, 3 parts of chitin, 15 parts of marine fish oligopeptide powder, 40 parts of gynura procumbens, 15 parts of medlar, 12 parts of mulberry leaves, 26 parts of combined spicebush leaves and 52 parts of poria cocos.

3. The process for preparing a urea-lowering composition according to claim 1 or 2, characterized in that: the method comprises the following steps:

4. The method of claim 3, wherein: in the step (1), the step (c),

and/or

5. The method of claim 3, wherein: in the step (3), the parameters of the spray drying are as follows: the inlet air temperature is 150-165 ℃, the outlet air temperature is 85-95 ℃, the feeding speed is 3.5-4.0Hz, and the tower pressure difference is kept between-100 Pa and-200 Pa.

6. The method of claim 3, wherein: in the step (4), the step (c),

and/or

7. Use of the composition according to claim 1 or 2 for the preparation of a medicament, health food or food composition for lowering uric acid.

8. A pharmaceutical, health food or food composition comprising the composition according to claim 1 or 2 as an active ingredient.

9. The pharmaceutical, nutraceutical, or food composition of claim 8, wherein: also comprises auxiliary materials or auxiliary components acceptable in the fields of pharmacy, health products or food.